GlassScriptPhysician profile
Anjana A Pillai
NPI 1154591428
$115,361.51
in general payments reported to CMS, 2019-2025
14 companies · $33K in 2025
The $33K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $6,620 · 2021: $8,668 · 2022: $4,315 · 2023: $9,009 · 2024: $22K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Consulting Fee: $28K · Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,877.24 |
| Consulting Fee | $28,434.25 |
| Food and Beverage | $1,968.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $41,648.05 | 2024-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Administration Set, Therasphere Y90 Glass Microspheres 10 Gbq |
| Eisai INC. | $27,906.95 | 2019-2022 | |
| Genentech, INC. | $15,223.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $10,303.99 | 2021-2025 | Imfinzi |
| Genentech USA, INC. | $5,978.61 | 2020-2023 | Tecentriq |
| Fujifilm Healthcare Americas Corporation | $4,838.46 | 2024-2025 | Utaswako Afp-L3 |
| Sirtex Medical INC | $3,000.00 | 2025 | Sir-Spheres Microspheres |
| Exelixis INC. | $2,812.56 | 2019 | |
| F. Hoffmann-La Roche Ag | $2,275.00 | 2021 | |
| Biocompatibles, INC. | $1,295.00 | 2019 | |
| Gilead Sciences, INC. | $27.07 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.42 | 2019 | |
| Dova Pharmaceuticals | $17.42 | 2019 | |
| Abbvie INC. | $14.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjana Pillai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.